Sign up
Pharma Capital

Oxford Biomedica CEO 'excited' about potential for LentiVector technology

John Dawson, chief executive of the specialist gene and cell therapy biopharmaceutical company Oxford Biomedica (LON:OXB) speaks to Proactive about their LentiVector platform, strategic approach and commercial strategy.

 

View full OXB profile

Oxford Biomedica Timeline

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.